公开(公告)号：US20220099690A1

公开(公告)日：2022-03-31

申请号：US17643260

申请日：2021-12-08

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Ruediger Laubender

IPC: G01N35/00 ,  G16H40/40 ,  G16H10/40 ,  G05B23/02

Abstract: A computer-implemented method for determining failures in laboratory equipment comprising: a) receiving a desired probability of false rejection ({hacek over (P)}fr) and a desired error detection rate ({hacek over (E)}D), such as a desired probability of error detection ({hacek over (P)}ed), relating to one or more QC levels (J) of quality control (QC) samples to be processed by the equipment; b) setting a number of runs (R) to one; c) calculating an error detection rate (ÊD) based at least partially on R; d) determining if ÊD is below {hacek over (E)}D, and if so: increase R by one, and repeat steps c) to d), and if not: define a rule for determining failures in the laboratory equipment based, at least partially, on R; e) receiving or collecting standardized QC results; f) applying the rule defined in step d) to the standardized QC results; g) determining failures in the equipment, if the standardized QC results comply with the rule.

公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20180231557A1

公开(公告)日：2018-08-16

申请号：US15952731

申请日：2018-04-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Vinzent Rolny ,  Farshid Dayyani ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Julia Riedlinger ,  Felix Herth ,  Thomas Muley

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N33/57484 ,  G01N2333/4742 ,  G01N2333/70596

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.

公开(公告)号：US20150192587A1

公开(公告)日：2015-07-09

申请号：US14463975

申请日：2014-08-20

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Norbert Wild ,  Ursula Garczarek ,  Andrea Geistanger ,  Herbert Andres ,  Marie-Luise Hagmann ,  Johann Karl ,  Friedemann Krause ,  Michael Pfeffer ,  Wolfgang Rollinger ,  Michael Tacke ,  Michael Thierolf

IPC: G01N33/574

CPC classification number: G01N33/57419 ,  C12Q1/6886 ,  G01N2333/4727 ,  G01N2333/805 ,  G01N2333/8146 ,  G01N2333/9121

Abstract: The present invention relates to the diagnosis of colorectal cancer. It discloses the use of protein S100A12 in the diagnosis of colorectal cancer. It relates to a method for diagnosis of colorectal cancer from a stool sample, derived from an individual by measuring S100A12 in said sample. Measurement of S100A12 can, e.g., be used in the early detection or diagnosis of colorectal cancer.

公开(公告)号：US20150268251A1

公开(公告)日：2015-09-24

申请号：US14730615

申请日：2015-06-04

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Christian Zaugg ,  Dirk Block ,  Ursula-Henrike Wienhues-Thelen ,  Hans-Peter Brunner ,  Friedemann Krause ,  Fabian Model ,  Vincent Rolny

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8139 ,  G01N2800/325 ,  G01N2800/52 ,  G01N2800/60

Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention. The present invention also relates to a system for identifying a subject being eligible to the administration of at least one medicament as disclosed herein and to reagents and kits used in performing the methods as disclosed herein.

Abstract translation: 本发明涉及一种用于鉴定有资格给予选自β-阻滞剂，醛固酮拮抗剂，利尿剂和肾素 - 血管紧张素系统抑制剂的至少一种药物的受试者的方法。 该方法基于选自GDF-15（生长分化因子15），内皮抑素，mimecan，IGFBP7（IGF结合蛋白7），心肌肌钙蛋白，BNP-15的至少一种生物标志物的量的测定。 来自患有心力衰竭的受试者的样品中的类型肽，尿酸，Gal3（Galectin-3），骨桥蛋白，sST2（可溶性ST2），PlGF，sFlt-1，P1NP，半胱氨酸蛋白酶抑制剂C，前白蛋白和转铁蛋白。 此外，该方法包括将所确定的量与参考量进行比较的步骤。 本发明进一步设想的是适用于实施本发明方法的试剂盒和装置。 本发明还涉及用于鉴定合适的给予本文公开的至少一种药物的受试者的系统以及用于执行本文所公开的方法的试剂和试剂盒。